Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Q2 2025 Results Conference Call July 17, 2025 9:00 AM ETCompany ParticipantsMichael Comilla - Vice President of ...

The Motley Fool. DATE Thursday, July 17, 2025 at 9 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Robert ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, 2025. This analyst has an accuracy rate of 66%. Stifel analyst Rick Wise ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott posted Q2 revenue of $11.14 billion and EPS of $1.26, raised 2025 earnings guidance, and saw strong growth in diabetes ...

In the first quarter of 2025, the company delivered strong earnings and outperformed a group of medical device peers, despite challenging conditions driven by tariffs.

Big bank earnings, June CPI inflation data, and U.S. retail sales, along with updates from TSMC, Netflix and Johnson & ...